Promote a Clinical Trial


Study of Zanubrutinib (BGB-3111) in Patients With Marginal Zone Lymphoma

This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL).

Sponsored by: BeiGene